What is MS Phase 3 Study CombiRx?

Category: Others

false

See also: Clinical Trial

NCT00211887 is a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in patients with relapsing-remitting multiple sclerosis. Other study IDs include: NS045719, 02-0526, CRC, U01 NS45719 and CombiRx.

Dosages

Most common dosages (by patients currently using MS Phase 3 Study CombiRx)
Dosage Patients
1 other daily 1
Last updated:
There are no evaluations for MS Phase 3 Study CombiRx.